Abstract
Abametapir is a new metalloproteinase inhibitor that received Food and Drug Administration approval in July 2020 as a topical pediculocide. The uniqueness of this new drug is that it targets metalloproteinase needed for hatching the eggs as well as killing adults. Herein we discuss this new drug, its history of development, its modality of use and its adverse drug reactions. It is hoped it will make Dermatologists aware of this new development.